145 related articles for article (PubMed ID: 16176490)
1. Raising the standards of trial-based economic evaluation: the devil is in the detail.
Backhouse ME
Value Health; 2005; 8(5):519-20. PubMed ID: 16176490
[No Abstract] [Full Text] [Related]
2. Taking clinical trials to task.
Drummond M
Value Health; 2005; 8(5):517-8. PubMed ID: 16176489
[No Abstract] [Full Text] [Related]
3. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
[TBL] [Abstract][Full Text] [Related]
4. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
Henry DA; Hill SR; Harris A
JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
[No Abstract] [Full Text] [Related]
5. Merging regulatory and reimbursement needs in clinical trials.
Cook JR
Value Health; 2015 Mar; 18(2):145-6. PubMed ID: 25773549
[No Abstract] [Full Text] [Related]
6. Why is the pharmaceutical industry investing increasing amounts in health economic evaluations?
Andersson F
Int J Technol Assess Health Care; 1995; 11(4):750-61. PubMed ID: 8567207
[TBL] [Abstract][Full Text] [Related]
7. Potential stifling effects of pharmaco-economics and regulatory policies.
Data JL
Am J Cardiol; 1998 Apr; 81(8A):34F-35F. PubMed ID: 9604904
[No Abstract] [Full Text] [Related]
8. Economic evaluation of drugs: a UK pharmaceutical industry perspective.
Wells N
Pharmacoeconomics; 1992 Jan; 1(1):14-9. PubMed ID: 10147036
[No Abstract] [Full Text] [Related]
9. Pharmacoeconomics is coming of age.
Pizzi L; Singh V
Clin Pharmacol Ther; 2008 Aug; 84(2):188-90. PubMed ID: 18679179
[No Abstract] [Full Text] [Related]
10. The use of pharmacoeconomic data in formulary selection.
Hatoum HT; Freeman RA
Top Hosp Pharm Manage; 1994 Jan; 13(4):47-53. PubMed ID: 10130683
[TBL] [Abstract][Full Text] [Related]
11. Drug therapy: safety, effectiveness, and economics.
Brandys J
Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340
[TBL] [Abstract][Full Text] [Related]
12. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
[TBL] [Abstract][Full Text] [Related]
13. Use and misuse of pharmacoeconomic terms: a definitions primer.
Sanchez LA; Lee J
Top Hosp Pharm Manage; 1994 Jan; 13(4):11-22. PubMed ID: 10184005
[TBL] [Abstract][Full Text] [Related]
14. Quality of clinical and economic evidence in dossier formulary submissions.
Colmenero F; Sullivan SD; Palmer JA; Brauer CA; Bungay K; Watkins J; Neumann PJ
Am J Manag Care; 2007 Jul; 13(7):401-7. PubMed ID: 17620035
[TBL] [Abstract][Full Text] [Related]
15. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomics: a managed care perspective.
Clouse JC
Top Hosp Pharm Manage; 1994 Jan; 13(4):54-9. PubMed ID: 10130684
[TBL] [Abstract][Full Text] [Related]
17. The link between gross profitability and pharmaceutical R&D spending.
Scherer FM
Health Aff (Millwood); 2001; 20(5):216-20. PubMed ID: 11558706
[No Abstract] [Full Text] [Related]
18. ISPOR's Initiative on US Value Assessment Frameworks: A Missed Opportunity for ISPOR and Patients.
Perfetto EM
Value Health; 2018 Feb; 21(2):169-170. PubMed ID: 29477396
[No Abstract] [Full Text] [Related]
19. Data briefing. The NICE threshold.
Appleby J
Health Serv J; 2007 Sep; 117(6074):21. PubMed ID: 17970386
[No Abstract] [Full Text] [Related]
20. Pharmaceutical industry research and cost savings in community-acquired pneumonia.
Kessler LA; Waterer GW; Barca R; Wunderink RG
Am J Manag Care; 2002 Sep; 8(9):798-800. PubMed ID: 12234020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
